Bladder Cancer Advocacy Network (BCAN) Think Tank 2025

Viewing 1-13 of 13 articles

BCANTT 2025: Balancing Innovation and Affordability: Collaborative Pathways in Bladder Cancer Care

BCANTT 2025: Exploring Therapeutic Vulnerabilities for Drug Development in Bladder Cancer Using down Syndrome as a Novel Model

BCANTT 2025: Overcoming Immune Suppressive Myeloid Cell Barriers in Bladder Cancer

BCANTT 2025: Tracking and Tackling an Increasing Trend in Young-Onset Bladder/Urothelial Cancer

BCANTT 2025: Elucidating Effects of Nutrition on the Microbiome and Immunotherapy Efficacy

BCANTT 2025: Lessons Learned from the SWOG S1011 Clinical Trial

BCANTT 2025: Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies

BCANTT 2025: Navigating Intergroup Collaboration in Clinical Trials Lessons from Leading the S1806 Trial (SWOG/NRG)

BCANTT 2025: The PRIME (S1602) Trial: Effectiveness of Different Bacillus Calmette-Guérin (BCG) Regimens in Patients with CIS, High-Grade Ta, or High-Grade T1 Non–muscle-Invasive Bladder Cancer (NMIBC)

BCANTT 2025: Patients Perspective on Design of Clinical Trials

BCANTT 2025: CALGB 90601: From Lemons to Lemonade, Possibilities from Negative Cooperative Group Trials

BCANTT 2025: EA8192 for UTUC Leadership and Career Opportunities in a Rare Tumor Cooperative Group Trial

BCANTT 2025: Alliance A031501: AMBASSADOR Study. Managing a Cooperative Group Study in a Rapidly Evolving Treatment Landscape